Active immunization against macrophage migration inhibitory factor using a novel DNA vaccine prevents ovariectomy-induced bone loss in mice

Vaccine

Volumn 26, Issue 6, 2008, Pages 829-836

  Onodera, Shin ^a   Oshima, Shigeki ^a   Nishihira, Jun ^b   Yasuda, Kazunori ^a   Tohyama, Harukazu ^a   Irie, Kazuharu ^c   Koyama, Yoshikazu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO INFORMATION UNIVERSITY   (Japan)

^c Health Sciences University of Hokkaido   (Japan)

Author keywords

Macrophage migration inhibitory factor; Ovariectomy; Vaccine

Indexed keywords

AUTOANTIBODY; COMPLEMENTARY DNA; DNA VACCINE; EPITOPE; MACROPHAGE MIGRATION INHIBITION FACTOR; OLIGONUCLEOTIDE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FEMALE; FEMUR; HELPER CELL; HISTOPATHOLOGY; MACROPHAGE; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; TRABECULAR BONE;

ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; DNA, COMPLEMENTARY; EPITOPES, T-LYMPHOCYTE; FEMALE; INJECTIONS, INTRAMUSCULAR; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED BALB C; OSTEOPOROSIS; OVARIECTOMY; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION; VACCINES, DNA;

EID: 38349048495     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.066     Document Type: Article

References (43)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 6 (2001) 785-795
2. Manolagas S.C., Kousteni S., and Jilka R.L. Sex steroids and bone. Recent Prog Horm Res 57 (2002) 385-409
3. Rogers A., and Eastell R. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone 29 1 (2001) 30-34
4. Pfeilschifter J., Koditz R., Pfohl M., and Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23 1 (2002) 90-119
5. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11 8 (1996) 1043-1051
6. Van Bezooijen R.L., Farih-Sips H.C., Papapoulos S.E., and Lowik C.W. IL-1alpha, IL-1beta, IL-6, and TNF-alpha steady-state mRNA levels analyzed by reverse transcription-competitive PCR in bone marrow of gonadectomized mice. J Bone Miner Res 13 2 (1998) 185-194
7. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257 5066 (1992) 88-91
8. Teitelbaum S.L. Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc Natl Acad Sci USA 101 48 (2004) 16711-16712
9. Bloom B.R., and Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153 731 (1966) 80-82
10. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56 1 (1966) 72-77
11. Weiser W.Y., Temple P.A., Witek-Giannotti J.S., Remold H.G., Clark S.C., and David J.R. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 86 19 (1989) 7522-7526
12. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365 6448 (1993) 756-759
13. Nishino T., Bernhagen J., Shiiki H., Calandra T., Dohi K., and Bucala R. Localization of macrophage migration inhibitory factor (MIF) to secretory glanules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1 7 (1995) 781-788
14. Calandra T., Bernhagen J., Mitchell R.A., and Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179 6 (1994) 1895-1902
15. Baugh J.A., and Donnelly S.C. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 179 1 (2003) 15-23
16. Ashcroft G.S., Mills S.J., Lei K., Gibbons L., Jeong M.J., Taniguchi M., et al. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest 111 9 (2003) 1309-1318
17. Hardman M.J., Waite A., Zeef L., Burow M., Nakayama T., and Ashcroft G.S. Macrophage migration inhibitory factor: a central regulator of wound healing. Am J Pathol 167 6 (2005) 1561-1574
18. Oshima S., Onodera S., Amizuka N., Li M., Irie K., Watanabe S., et al. Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomy-induced bone loss. FEBS Lett 580 5 (2006) 1251-1256
19. Kitazawa R., Kimble R.B., Vannice J.L., Kung V.T., and Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 94 6 (1994) 2397-2406
20. Kimble R.B., Matayoshi A.B., Vannice J.L., Kung V.T., Williams C., and Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136 7 (1995) 3054-3061
21. Kimble R.B., Bain S., and Pacifici R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 12 6 (1997) 935-941
22. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 2 (1997) 309-319
23. Onodera S., Ohshima S., Tohyama H., Yasuda K., Nishihira J., Iwakura Y., et al. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 56 2 (2007) 521-530
24. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 2 (1991) 193-199
25. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., and Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19 12 (1989) 2237-2242
26. Aihara H., and Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotech 16 9 (1998) 867-870
27. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 6 (1987) 595-610
28. Riggs B.L., Khosla S., Atkinson E.J., and Dunstan C.R. Melton LJ 3rd Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporosis Int 14 9 (2003) 728-733
29. Lindsay R. Prevention and treatment of osteoporosis. Lancet 341 8848 (1993) 801-805
30. Onodera S., Sasaki S., Ohshima S., Amizuka N., Li M., Udagawa N., et al. Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J Bone Miner Res 21 6 (2006) 876-885
31. Bernhagen J., Mitchell R.A., Calandra T., Voelter W., Cerami A., and Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33 47 (1994) 14144-14155
32. Morand E.F., and Leech M. Macrophage migration inhibitory factor in rheumatoid arthritis. Front Biosci 10 (2005) 12-22
33. Leech M., Metz C., Hall P., Hutchinson P., Gianis K., Smith M., et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42 8 (1999) 1601-1608
34. Morand E.F., Bucala R., and Leech M. Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis. Arthritis Rheum 48 2 (2003) 291-299
35. Weitzmann M.N., Roggia C., Toraldo G., Weitzmann L., and Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 110 11 (2002) 1643-1650
36. Toraldo G., Roggia C., Qian W.P., Pacifici R., and Weitzmann M.N. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 100 1 (2003) 125-130
37. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16 2 (2001) 348-360
38. Shaughnessy S.G., Walton K.J., Deschamps P., Butcher M., and Beaudin S.M. Neutralization of interleukin-11 activity decreases osteoclast formation and increases cancellous bone volume in ovariectomized mice. Cytokine 20 2 (2002) 78-85
39. Juji T., Hertz M., Aoki K., Horie D., Ohya K., Gautam A., et al. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. J Bone Miner Metab 20 5 (2002) 266-268
40. Spohn G., Schwarz K., Maurer P., Illges H., Rajasekaran N., Choi Y., et al. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol 175 9 (2005) 6211-6218
41. Jouvenne P., Fossiez F., Banchereau J., and Miossec P. High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study. Scand J Immunol 46 4 (1997) 413-418
42. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 17 7 (1999) 666-669
43. Zagury D., Le Buanec H., Bizzini B., Burny A., Lewis G., and Gallo R.C. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 14 2 (2003) 123-137